

British Paediatric Neurology Association
Annual Conference 16-18 January 2008, Leeds
Draft Programme (updated 18 October 2007)

Wednesday 16 January 2008

- Noon Conference Registration and Lunch
- 13.00 – 13.05 Welcome
- 13.05 – 14.35 **Session 1: Oral Presentations**
- 13.05** SCN1A mutation analysis aids early diagnosis of infantile onset epilepsies Dr S Zuberi
- 13.20** Inherited SCN1A mutation in siblings with Panayiotopoulos syndrome Dr J Livingston
- 13.35** Longitudinal cognitive profile in infant onset epilepsy Dr A Whitney
- 13.50** Phenotypic characterization of a large family with benign familial neonatal seizures associated with an exon duplication of the KCNQ2 gene Dr R Lunan
- 14.05** Efficacy and tolerability of the ketogenic diet in drug resistant epilepsy: a randomised controlled trial of classical and medium chain triglyceride protocols Mrs E Neal
- 14.20** Extreme drug toxicity with Clobazam due to genetic polymorphism masquerading as factitious or induced illness Dr R Hughes
- 14.30 – 15.00 **Keynote lecture: ‘Restorative technologies for children with disability: is it all hype?’**
*Professor Bippin Bhakta, Charterhouse Professor in Rehabilitation Medicine
University of Leeds*
- 15.00 – 16.30 Poster viewing (tea & coffee will be served)
- 16.30 – 17.00 Presentations by Guests of the BPNA
- 17.00 - Eulogy for Dr Robert Surtees by Professor Brian Neville
- 17.00 – 19.00 Annual General Meeting of the British Paediatric Neurology Association
- 20.00 for 20.30 Dinner

Thursday 17 January 2008

08.00 – 09.00 **Personal practice sessions:**

1. The management of non-organic disorders that present to the neurologist
Led by Dr M Eminson & Dr D Cotterill
2. The practical management of increased muscle tone
Led by Dr M Clarke & Dr N Basheer

09.00 – 10.30 **Session 2: Oral Poster Presentations**

- | | | |
|-------|--|-----------------|
| 09.00 | Measuring tympanic membrane displacement in raised intracranial pressure | Dr M Lim |
| 09.05 | Bannayan-Riley-Ruvalcaba syndrome: a common cause of extreme macrocephaly and neurodevelopmental delay | Dr N Lynch |
| 09.10 | Factors influencing admission to ICU in children presenting with status epilepticus (SE) | Dr S Tirupathi |
| 09.15 | A simple screening test for defects in creatine metabolism | Dr S Hogg |
| 09.20 | A contributory role for neuroinflammation in Batten disease | Dr M Lim |
| 09.25 | Making the diagnosis in leukoencephalopathy - key features in a cohort of children with Pelizaeus Merzbacher disease | Dr A Maw |
| 09.30 | Infantile Parkinsonism- dystonia with raised CSF dopamine metabolites | Dr J Ng |
| 09.35 | Acute necrotising encephalopathy (ANE), associated with a missense mutation in the nuclear pore component ran binding protein 2 (RANBP2) | Dr A-M Childs |
| 09.40 | Posterior reversible leucoencephalopathy syndrome (PRES) as a presentation of Guillain Barre syndrome (GBS) in a child | Dr A Desurkar |
| 09.45 | Novel neuro-renal syndrome due to AQP4 antibody mediated disease | Dr V Ramesh |
| 09.50 | Dominantly inherited leucoencephalopathy with recurrent haemorrhagic stroke due to COL4A1 mutation | Dr S Shah |
| 09.55 | Diffuse hemispheric DNET: a new radiological variant associated with early onset severe epilepsy | Dr K Sarsfield |
| 10.00 | Primary diffuse leptomeningeal melanosis mimicking tuberculous meningitis | Dr V Jain |
| 10.05 | Double trouble: central core myopathy with RYR1 mutation masks 5q spinal muscular atrophy | Dr S Chandratre |
| 10.10 | Congenital myasthenia due to COLQ gene mutation responsive to ephedrine therapy | Dr R Pandey |
| 10.15 | Establishing the parameters for clinical trials of antisense oligonucleotide therapy in Duchenne muscular dystrophy | Dr M Kinali |

- 10.20 Long-term use of intermittent low-dosage prednisolone therapy in Duchenne muscular dystrophy, tolerance and effect on functional outcome Dr M Kinali
- 10.25 Perinatal dyskinesia as a presenting feature in Prader Willi syndrome Dr N McSweeney
- 10.30 – 11.00 **Keynote lecture: ‘Aicardi-Goutières syndrome and other genetic causes of intracranial calcification’**
Dr Yanick Crow, Senior Lecturer and Honorary Consultant in Clinical Genetics, Institute of Molecular Medicine, St James’s University Hospital, Leeds
- 11.00 – 11.30 Tea and coffee break
- 11.30 – 12.00 **Session 3: Oral Presentations**
- 11.30 Health related quality of life (HRQL) and its determinants at 1, 6 and 12 months in Traumatic Brain Injury (TBI) children and non-injured controls Dr B Hameed
- 11.45 Bringing back the child: development after extreme deprivation Dr L-J Brown
- 12.00 – 13.00 **Ronnie MacKeith Guest Lecture: ‘Sam and Ronnie: attention and personality’**
Professor George Rousseau, Co-Director, Oxford University Centre for the History of Childhood
- 13.00 – 14.00 Lunch
- 14.00 – 15.00 **Session 4: Oral Presentations**
- 14.00 Innovative speech and language therapy for school age children with language impairment: findings from a randomised controlled trial Prof A O’Hare
- 14.15 Botulinum toxin type A as a treatment of pain in cerebral palsy Dr C Lundy
- 14.30 Parent and child perception of nitrous oxide use for botulinum toxin injections of upper and lower limb spasticity Dr K Pysden
- 14.45 Deep brain stimulation improves motor ability and reported quality of life in primary and secondary generalised dystonia Dr T Kerr
- 15.00 – 17.00 Special Interest Group meetings (details in the conference handbook)
- 19.30 for 20.00 Reception, dinner and ceilidh

Friday 18 January 2007

08.00 – 09.00 **Personal practice sessions:**

1. Optimal management of CNS Tumour
Led by Dr S Picton, Mr P Chumas & Dr J Livingston
2. The management of newly diagnosed epilepsy
Led by Dr C Ferrie & Dr T Martland

09.00 – 10.30 **Session 5: Oral Presentations**

- | | | |
|-------|--|-------------------|
| 09.00 | Spectrum of brain involvement in muscular dystrophies with defective dystroglycan glycosylation | Prof F Muntoni |
| 09.15 | Dystrophin positive revertant fibres do not increase with age in Duchenne muscular dystrophy | Dr M Kinali |
| 09.30 | Hereditary Motor Sensory Neuropathy (HMSN) with superadded inflammatory polyneuropathy in two children | Dr A Desurkar |
| 09.45 | Congenital myasthenic syndromes in childhood: diagnostic pitfalls and management issues | Dr S Robb |
| 10.00 | A national prospective population-based study of children with mitochondrial disease: clinical presentation and method of diagnosis in 101 cases | Dr D Krishnakumar |
| 10.15 | Significant variation in the prevalence and spectrum of neuromuscular disease among different ethnic groups: an observational study | Dr A-M Childs |

10.30 – 11.00 **Keynote lecture: 'The delivery of paediatric neurosurgery: a time for change'**
Mr Paul Chumas, Consultant Paediatric Neurosurgeon, Leeds

11.00 – 11.30 Tea and coffee break

11.30 – 12.00 **Ronnie MacKeith Prize Lecture**

12.00 – 13.15 **Session 6: Oral Presentations**

- | | | |
|-------|---|----------------|
| 12.00 | Improving the yield of investigations in mitochondrial disorders | Dr A Parker |
| 12.15 | The use of aciclovir in children with possible viral encephalitis | Dr R Kneen |
| 12.30 | Cerebrovascular dysplasia in neurofibromatosis Type 1 | Dr A Cairns |
| 12.45 | Use of cerebral Magnetic Resonance Imaging (MRI) and Transcranial Doppler (TCD) to monitor cerebral vascular and perfusion abnormalities in children with sickle cell disease: the Irish experience | Dr N Lynch |
| 13.00 | Neurological complications associated with isolated liver transplant – a retrospective long term study | Dr T El-Azzabi |

13.15 – 14.00 Lunch

14.00 – 15.00 **Session 7: Video session with oral presentations**

- | | | |
|-------|--|-----------------|
| 14.00 | Hereditary neuralgic amyotrophy: a differential for recurrent shoulder pain and weakness | Dr S Chandratre |
| 14.12 | Improved motor function and resumption of speech and oral feeding in a case of non-DYT1 idiopathic torsion dystonia following pallidal deep brain stimulation (DBS). | Dr T Kerr |
| 14.24 | Movement disorders associated with complex regional pain syndrome | Dr S Agrawal |
| 14.36 | Paroxysmal episodes, “re-build up” phenomenon and moyamoya disease | Dr N Dlamini |
| 14.48 | Creatine synthesis disorder: atypical presentation of a treatable disorder | Dr D O’Rourke |

15.00 – 15.30 Case discussion

15.30 Tea and coffee prior to journey home